Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564716 | 0.81 | — | — | |
| SCHEMBL1565026 | 0.81 | KHK (0.33) | — | |
| SCHEMBL20576641 | 0.79 | KHK (0.34) | KDM4EHSD17B10TLR8 | |
| SCHEMBL16246665 | 0.78 | KDM4E (0.41) | LMNAALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL17591654 | 0.77 | KDM4E (0.49) | LMNAALDH1A1HPGDAPOBEC3GKDM4E | |
| SCHEMBL15544985 | 0.76 | — | — | |
| SCHEMBL15274416 | 0.75 | KDM4E (0.32) | ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL19204032 | 0.73 | GAA (0.38) | LMNAALDH1A1HPGD | |
| SCHEMBL5818365 | 0.71 | KDM4E (0.51) | LMNAALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL4068566 | 0.71 | ALDH1A1 (0.35) | LMNAALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101448827-A | Indole derivatives | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | LMNA 3520/4885ALDH1A1 1318/4885HPGD 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.